Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progerinin in Hutchinson-Gilford Progeria Syndrome
NCT06775041Phase 2Completed
- Sponsor
- PRG Science & Technology
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Progerinin in Hutchinson-Gilford progeria syndrome (HGPS) (3 arms), sponsored by PRG Science & Technology. Primary endpoints: Change from baseline in plasma progerin concentration at Month 4, Incidence of Dose Limiting Toxicities and 19 more. Started Jan 2025; status: completed.
02
Drugs
Progerinin
03
Conditions
Hutchinson-Gilford progeria syndrome (HGPS)
Beyond the preview
Go deeper on NCT06775041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775041.